Agenda

Welcome Reception

Breakfast and Registration

Welcome and Opening Remarks From the Co-Chairs
Chairs: John Gribben, MD, DSc FRCP, FRCPath, FMed Sci and Jason Westin, MD, MS, FACP, FASCO

Session 1: Controversies in T-Cell Lymphoma
Chairs: Laurence de Leval, MD, PhD and Francine Foss, MD

What do we need to make faster progress in T-cell lymphoma?

• Translational Gaps – Ahmet Dogan, MD, PhD
• Clinical Gaps – Steven Horwitz, MD
• How do we advance clinical trials to move the therapeutic bar in peripheral T-cell lymphomas? – Kerry Savage, MD, MSc
• Panel Discussion – Moderated by Session Chairs

Session 2: Controversies in Mantle Cell Lymphoma
Chair: Stephen Ansell, MD, PhD

Sequencing therapy in MCL: too many options for too few patients?

• Who Will Receive Chemotherapy in 2030? – Christine Ryan, MD
• What Do We Need for Biomarker-Informed Risk-Adapted Therapy? – Yucai Wang, MD, PhD
• Panel Discussion – Moderated by Session Chairs

Coffee Break

Session 3: Keynote Address
Chairs: John Gribben, MD, DSc FRCP, FRCPath, FMed Sci and Rebecca King, MD

• The Potential of ctDNA as an Outcome Predictor in Lymphoma – Ash A. Alizadeh, MD, PhD
• Panel Discussion – Moderated by Session Chairs

Session 4: Translational Research in Aggressive Lymphomas
Chairs: Margaret Shipp, MD and Jason Westin, MD, MS, FACP, FASCO

• Molecular Signatures Across Aggressive B-Cell Lymphomas: What Truly Defines Risk in 2026? – Bjorn Chapuy, MD, PhD
• Multimodal Integration: PET, ctDNA, and Genomics—Are We Measuring the Same Risk? – Mark Roschewski, MD
• Treatment Resistance: Known and Unknown (Chemotherapy, BTKi, BsAbs, CAR T) – Ryan Morin, PhD
• Panel Discussion – Moderated by Session Chairs

Lunch

Session 5: Novel Therapies
Chair: Laurie Sehn, MD, MPH and TBC

• BTKi Combinations – Pier Luigi Zinzani, MD, PhD
• BTK Degraders – Inhye Ahn, MD
• BCL6 Degraders – David Qualls, MD
• CELMoDs – Marc Hoffmann, MD
• ADCs – Gilles Salles, MD, PhD
• Panel Discussion – Moderated by Session Chairs

Session 6: Expanding CAR T-Cell Therapy
Chairs: Catherine Bollard, MBBCh, MD and Jason Westin, MD, MS, FACP, FASCO

• Commercially-Available CD19 Autologous CAR T-Cell Therapies in NHL – TBC
• Late-Stage CD19 Allogeneic CAR T-Cell Therapies in NHL – Sattva Neelapu, MD
• In vivo CARs – TBC
• CD19/CD20 – Saurabh Dahiya, MD
• CD19/CD22 – David Miklos, MD, PhD
• CD20/CD22 – TBC
• Panel Discussion – Moderated by Session Chairs

Coffee Break

Session 7: Patient Advocacy in Lymphoma
Chair: John Gribben, MD, DSc FRCP, FRCPath, FMed Sci

• How Do We Increase the Patient Voice in Lymphoma Clinical Trials? The Role of the Lymphoma Coalition – Lorna Warwick, CEO, Lymphoma Coalition
• Panel Discussion – Moderated by Session Chair

Session 8: Debate–CAR T-Cell Failure, Is it the Target or the Microenvironment?
Chair: David Maloney, MD, PhD and TBC

• Target – David Miklos, MD, PhD
• Microenvironment – Sairah Ahmed, MD
• Panel Discussion – Moderated by Session Chair

Breakfast

Session 9: Bispecific and Trispecific Antibodies in NHL–Combinations in First- and Second-Line Treatment
Chairs: Martin Hutchings, MD, PhD and Marion Subklewe, MD

• Epcoritamab – Martin Hutchings, MD, PhD
• Glofitamab – TBC
• Mosunetuzumab – Elizabeth Budde, MD, PhD
• Odronextamab – TBC
• Other Bispecifics – Mazyar Shadman, MD, MPH
• Trispecifics – Paolo Strati, MD
• Panel Discussion – Moderated by Session Chairs

Session 10: AI Is Coming
Chair: TBC

• Presentation – Swami Iyer, MD
• Panel Discussion – Moderated by Session Chair

Coffee Break

Session 11: CAR T-Cells Stuck in Second Gear–Practical Discussion on Expanding Access
Chairs: Loretta Nastoupil, MD and Miguel Perales, MD

• Academic Focus – Tanya Siddiqi, MD
• Community Focus – Loretta Nastoupil, MD
• Patient Advocate Focus – Lorna Warwick, CEO Lymphoma Coalition
• Panel Discussion – Moderated by Session Chairs

Lunch

Session 12: MRD Testing in NHL–How and What to Implement
Chair: Mark Roschewski, MD

• MRD Implementation Presentation – Mark Hamilton, MD, PhD
• Panel Discussion – Moderated by Session Chair

Session 13: How Can We Succeed With:
Chair: TBC

• Bispecific Antibodies in Community Practice – Tara Graff, DO, MS
• Outpatient CAR T-Cell Therapy – Olalekan Oluwole, MD
• Digital Pathology – TBC
• AI and Radiology – TBC
• Panel Discussion – Moderated by Session Chair